Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics...
Buona capitalizzazione fino al 2026 con capacità di finanziamento al 100% dell'asset principale EryDex, con in programma uno studio di fase 3...
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA...
FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...
false 0001662774 0001662774 2023-05-24 2023-05-24 0001662774 us-gaap:CommonStockMember 2023-05-24 2023-05-24 0001662774...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.